A trial looking at apitolisib with everolimus for kidney cancer that has spread (ROVER)

Cancer type:

Kidney cancer
Renal cell cancer
Secondary cancers




Phase 2

This trial compared apitolisib and everolimus for kidney cancer that had spread to another part of the body. It was for people with renal cell cancer (RCC).

The trial was open for people to join between 2011 and 2012. The team published the results in 2016.

More about this trial

Renal cell cancer is the most common type of kidney cancer in adults. 

When this trial was done, doctors sometimes used everolimus to treat advanced renal cell cancer. Everolimus is a type of targeted treatment called a cancer growth blocker. It stops the signals that cancer cells need to divide and grow.

Apitolisib (GDC-0980) is also a type of cancer growth blocker. It works in a slightly different way to everolimus. Researchers hoped that apitolisib may be better than everolimus to treat kidney cancer that has spread. 

People in this trial were put into a treatment group at random:

  • half had everolimus
  • half had apitolisib

The main aim of the trial was to find out if apitolisib is better than everolimus for kidney cancer that has spread.

Summary of results

As part of our editorial policy, any trial information we write is checked externally before we put it on our website. The research team have published some results for this trial. But we have been unable to find anyone involved with the trial to check the summary for us. 

This means we are not able to include a plain English summary of the results on this page.

More information
There is more information about this trial in the link to the medical journal below.  

Please note, the information we link to here is not in plain English. It has been written for healthcare professionals and researchers.

Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma
T Powles and others
Journal of Clinical Oncology (2016). Volume 34, issue 14, pages 1660 – 1668.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Professor Thomas Powles

Supported by

Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer

If you have questions about the trial please contact our cancer information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:


Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Last reviewed:

Rate this page:

Currently rated: 3 out of 5 based on 1 vote
Thank you!
We've recently made some changes to the site, tell us what you think